CANY
HRMY icon

Caxton Associates (New York)’s Harmony Biosciences HRMY Stock Holding History

Caxton Associates (New York)’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,389
Closed -$256K – 576
2024
Q3 		$256K Buy
+6,389
New +$224K 0.01% 460

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Caxton Associates (New York)'s HRMY Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Harmony Biosciences (HRMY) in Q4 2024, closing a stake of 6,389 shares — an estimated $256K sold.

Caxton Associates (New York) first reported a position in HRMY in Q3 2024 and held it in 1 quarter. The position peaked at $256K in Q3 2024. 247 funds tracked by Wall St. Rank hold HRMY as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Harmony Biosciences position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 6,389 Harmony Biosciences shares in Q4 2024, an estimated $256K.
  • Caxton Associates (New York) first reported a position in Harmony Biosciences in Q3 2024 and held it in 1 quarter.
  • Caxton Associates (New York)'s Harmony Biosciences position peaked at $256K in Q3 2024.
  • 247 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.